OCUL

12.50

0.20% 0.025

Handel nachbörslich: 11.89 -0.61 -4.88%

Ocular Therapeutix Inc (OCUL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt OCUL? Forum Prognose

Schlusskurs vom Vortag:

$12.47

Offen:

$12.59

24-Stunden-Volumen:

2.65M

Relative Volume:

1.15

Marktkapitalisierung:

$2.17B

Einnahmen:

$61.10M

Nettoeinkommen (Verlust:

$-138.36M

KGV:

-9.2593

EPS:

-1.35

Netto-Cashflow:

$-90.59M

1W Leistung:

+0.00%

1M Leistung:

+13.33%

6M Leistung:

+67.11%

1J Leistung:

+56.25%

1-Tages-Spanne:

$12.41

$12.91

1-Wochen-Bereich:

$11.96

$12.91

52-Wochen-Spanne:

$5.80

$12.91

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Firmenname

Ocular Therapeutix Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (646)

Telefon

781-357-4000

Adresse

15 CROSBY DRIVE, BEDFORD, MA

Mitarbeiter

274

Twitter

@OCUTX

Nächster Verdiensttermin

2025-03-03

Neueste SEC-Einreichungen

OCUL's Discussions on Twitter

Vergleichen Sie OCUL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
OCUL Ocular Therapeutix Inc	12.50	2.17B	61.10M	-138.36M	-90.59M	-1.35
VRTX Vertex Pharmaceuticals Inc	395.92	99.42B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	561.55	58.99B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	432.52	56.35B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	646.60	39.02B	3.05B	1.28B	-614.78M	19.58
ONC Beone Medicines Ltd Adr	307.51	34.25B	3.81B	-644.79M	-669.77M	-6.24

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-08	Eingeleitet	William Blair	Outperform
2025-03-18	Eingeleitet	RBC Capital Mkts	Outperform
2025-03-11	Eingeleitet	Needham	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-06-20	Hochstufung	TD Cowen	Hold → Buy
2024-05-31	Fortgesetzt	Piper Sandler	Overweight
2024-02-09	Eingeleitet	BofA Securities	Buy
2023-04-21	Eingeleitet	Robert W. Baird	Outperform
2022-08-10	Fortgesetzt	Berenberg	Buy
2021-08-10	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-28	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-12-17	Eingeleitet	Berenberg	Buy
2020-11-13	Bestätigt	Raymond James	Strong Buy
2020-08-10	Bestätigt	H.C. Wainwright	Buy
2020-03-03	Hochstufung	Raymond James	Outperform → Strong Buy
2019-05-21	Herabstufung	Cowen	Outperform → Market Perform
2019-05-21	Bestätigt	H.C. Wainwright	Buy
2019-05-21	Herabstufung	Raymond James	Strong Buy → Outperform
2018-12-03	Bestätigt	Cantor Fitzgerald	Overweight
2018-11-15	Eingeleitet	Raymond James	Strong Buy
2018-09-07	Eingeleitet	Piper Jaffray	Overweight
2017-10-24	Eingeleitet	Guggenheim	Buy
2017-07-26	Eingeleitet	H.C. Wainwright	Buy
2017-07-12	Bestätigt	Cantor Fitzgerald	Overweight
2017-06-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Eingeleitet	Cantor Fitzgerald	Overweight
2016-11-15	Bestätigt	RBC Capital Mkts	Outperform
2016-08-11	Eingeleitet	JMP Securities	Mkt Outperform
2016-02-17	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten

10:16 AM

Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI - Ophthalmology Times

10:16 AM

Aug 12, 2025

Ocular Therapeutix™ Receives FDA Agreement Under Special - GlobeNewswire

Aug 12, 2025

Ocular Therapeutix's AXPAXLI: A Game-Changer in Diabetic Retinopathy and Wet AMD Markets - AInvest

Aug 12, 2025

Ocular gets FDA agreement for registrational trial of Axpaxl - Seeking Alpha

Aug 12, 2025

Ocular Therapeutix secures FDA agreement for diabetic retinopathy trial By Investing.com - Investing.com Australia

Aug 12, 2025

Ocular Therapeutix Receives FDA Agreement on AXPAXLI Registrational Trial Design. - AInvest

Aug 12, 2025

Ocular Therapeutix Receives FDA Approval for Registrational Trial of AXPAXLI in NPDR, Plans to Outline Clinical Trial Design at Investor Day - AInvest

Aug 12, 2025

Revolutionary Once-Yearly Eye Treatment Gets FDA Trial Approval: Could Help 9M Diabetic Retinopathy Patients - Stock Titan

Aug 12, 2025

Weaker Q2 Results and Rising Losses Might Change the Case for Investing in Ocular Therapeutix (OCUL) - simplywall.st

Aug 12, 2025

Aug 10, 2025

Ocular Therapeutix Inc. Stock Poised for Technical ComebackLow Capital High Return Stock Plans Reviewed - beatles.ru

Aug 10, 2025

Aug 08, 2025

ETF Channel: ITOT Expected to Reach $154 - AInvest

Aug 08, 2025

Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter Report - Yahoo Finance

Aug 08, 2025

Aug 07, 2025

Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions - TipRanks

Aug 07, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - MSN

Aug 07, 2025

RBC Capital Maintains Buy Rating on Ocular Therapeutix with $17 Price Target - AInvest

Aug 07, 2025

Aug 06, 2025

Ocular Therapeutix stock hits 52-week high at 12.38 USD - Investing.com

Aug 06, 2025

Ocular Therapeutix: Q2 Earnings Snapshot - Huron Daily Tribune

Aug 06, 2025